The field of cancer continues to be the leading edge of personalized medicine. Cancer biomarkers are playing an ever-increasing role in the stratification of patient populations, the identification of new therapeutic targets, and the development of novel technologies. This conference focuses on topics paramount to the continuing progress of biomarker research and development. This two-day summit will bring together top leaders from the pharmaceutical and biotechnology communities, officials from the FDA and NIH, and researchers from esteemed academic institutions to discuss the landscape of research, the challenges of regulations, and the future of biomarker opportunities.